Pharming Group N.V. Business Summary

Pharming Group N.V. (PHAR) is a commercial-stage biopharmaceutical leader specializing in rare disease therapies, generating revenue through the global sale of its proprietary protein replacement and precision medicines. The company’s primary business segments are centered on two commercial assets: RUCONEST, a recombinant C1 esterase inhibitor for acute hereditary angioedema (HAE), and Joenja (leniolisib), the first-of-its-kind oral PI3Kδ inhibitor for activated PI3K delta syndrome (APDS). For the 2026 fiscal year, Pharming has guided total revenues between $405 million and $425 million, representing 8% to 13% growth over its 2025 preliminary revenue of approximately $376 million. In the competitive HAE landscape, Pharming competes directly with Takeda (Takhzyro, Firazyr), CSL Behring (Haegarda, Berinert), and BioCryst Pharmaceuticals (Orladeyo), maintaining a specialized niche as a provider of recombinant, non-plasma-derived treatments for acute attacks while aggressively expanding Joenja’s label into broader primary immunodeficiency (PID) and pediatric populations. Originally founded in 1988 through the merger of Genfarm B.V. and Chimera Biotech, Pharming is currently led by a high-pedigree executive team installed to drive its multi-product growth phase. Chief Executive Officer Fabrice Chouraqui, PharmD, MBA, joined in March 2025 following a tenure as CEO-Partner at Flagship Pioneering and President of Novartis Pharmaceuticals USA. He is supported by Chief Financial Officer Kenneth Lynard, who took office in October 2025 after serving as CFO of Zentiva and Senior Vice President/CFO of Global Commercial Operations at Gilead Sciences. Other key leaders include Chief Medical Officer Anurag Relan, MD, and Chief Commercial Officer Leverne Marsh. The company’s strategic direction is overseen by a one-tier Board of Directors chaired by Richard Peters, MD, PhD, and is backed by notable institutional investors including Orbimed and Deerfield Management.